Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.46 +0.58 (+2.78%)

Streaming Delayed Price Updated: 1:31 PM EDT, May 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,055,236
Open	20.93
Bid (Size)	21.47 (200)
Ask (Size)	21.48 (100)
Prev. Close	20.88
Today's Range	20.92 - 21.62
52wk Range	10.41 - 64.80
Shares Outstanding	93,148,652
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

April 22, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

Performance

YTD	+0.7%	+0.7%
1 Month	-1.4%	-1.4%
3 Month	+1.1%	+1.1%
6 Month	-7.7%	-7.7%
1 Year	-65.6%	-65.6%

More News

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

Via MarketMinute

The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine

March 26, 2026

Via Finterra

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine

March 25, 2026

Via Finterra

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

March 21, 2026

Via The Motley Fool

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 19, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗

March 16, 2026

Via Stocktwits

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 16, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

February 27, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

February 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Via Stocktwits

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗

February 25, 2026

Via Stocktwits

Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?

Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?

The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market

What is the current price of Sarepta Therapeutics, Inc. - Common Stock?

The current price of Sarepta Therapeutics, Inc. - Common Stock is 21.46

When was Sarepta Therapeutics, Inc. - Common Stock last traded?

The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 05/01/26 01:31 PM ET

What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?

The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 2.00B

How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?

Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.